At a glance
| Field | Details |
|---|---|
| Brand names | Not yet globally branded |
| Targets | GLP-1R + GCGR |
| Developer | Innovent Biologics / Eli Lilly |
| Modality | SC injection, once-weekly |
| Approval status | Approved — China 2025. Not yet approved US/EU |
| Key efficacy | ~14.5% weight loss at 24 weeks (Phase 3 GLORY, China) |
| Indications | Obesity |
User Sentiment
Mazdutide's patient community is in China, where it's approved. Western discussion is mostly among researchers and pipeline watchers. Chinese patient forums report outcomes consistent with the GLP-1/glucagon class — strong appetite suppression with the distinct energy expenditure increase the glucagon component produces.
Example(What the community says)
Chinese health platforms show active discussion among mazdutide patients noting that the drug "feels different" from GLP-1-only options — particularly around energy levels and the speed of early weight loss. The glucagon agonism raising metabolic rate appears experientially distinct from appetite suppression alone.
How it works
GLP-1/glucagon dual agonist — same receptor framework as survodutide and pemvidutide. GLP-1R handles appetite suppression and insulin. GCGR adds energy expenditure and hepatic fat targeting. Developed by Innovent with Eli Lilly's commercial involvement, and the first drug of this mechanistic type to receive regulatory approval anywhere in the world.
Definition(First in class — globally)
Regulatory firsts matter because they demonstrate that a mechanism is acceptable to regulators, establish the safety database expectations for the class, and force competitors to respond. Mazdutide's China 2025 approval is the first anywhere for GLP-1/glucagon dual agonism — before survodutide, before pemvidutide, before anything in the West. That means the Chinese NMPA has reviewed and accepted this mechanism for approval, establishing a precedent that Western regulators will note.
Trial data
GLORY trials (Phase 3, China, 24 weeks): ~14.5% weight loss. Shorter trial duration than Western comparators — the 24-week number likely understates the full efficacy at 48–72 weeks, consistent with how other GLP-1 class drugs show continuing weight loss beyond 24 weeks.
What to Expect
Based on Chinese Phase 3 GLORY data and GLP-1/glucagon mechanism:
Month 1–2 — GI side effects during titration, appetite reduction early.
Month 3–6 — 10–12% weight loss range at 24 weeks (GLORY data). Weight loss expected to continue past 24 weeks based on class behavior.
Energy and metabolism — The glucagon component's effect on resting metabolic rate is reported as a distinct "lighter" feeling by some patients, separate from reduced appetite.
Not available in the US or EU — global filing timeline not yet public.
Dosing and administration
Once-weekly subcutaneous injection per China-approved protocol. Global dosing pending Phase 3 [verify global trial design].
Development status
| Milestone | Status |
|---|---|
| China approval | 2025 |
| Global Phase 3 | [verify status] |
| FDA filing | Timeline not public |
Safety profile
Phase 3 data from China consistent with GLP-1/glucagon class profile. Full global safety database pending.
Who It's For
- Currently only available in China
- BMI ≥ 28 (Chinese obesity criteria differ from Western BMI thresholds)
- People with obesity and type 2 diabetes — both indications in the Chinese approval
Western patients: mazdutide's approval establishes the regulatory precedent for GLP-1/glucagon dual agonism. Survodutide and pemvidutide are the Western development path for this mechanism.
Summary(The mazdutide picture)
The first approved GLP-1/glucagon dual agonist, anywhere in the world. 14.5% at 24 weeks likely understates full efficacy — most GLP-1 drugs continue losing weight through 48–72 weeks. The Lilly partnership provides commercial infrastructure; the global filing timeline is the key question.